Walleye Capital LLC Acquires Shares of 138,575 OptimizeRx Co. (NASDAQ:OPRX)

Walleye Capital LLC purchased a new stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 138,575 shares of the company's stock, valued at approximately $673,000. Walleye Capital LLC owned about 0.75% of OptimizeRx as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of OPRX. Whetstone Capital Advisors LLC bought a new stake in OptimizeRx during the 4th quarter worth $6,563,000. Royce & Associates LP bought a new stake in shares of OptimizeRx in the 4th quarter valued at about $5,198,000. Kennedy Capital Management LLC grew its position in shares of OptimizeRx by 57.8% in the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock valued at $2,887,000 after buying an additional 217,676 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of OptimizeRx by 670.3% in the 4th quarter. JPMorgan Chase & Co. now owns 59,952 shares of the company's stock valued at $291,000 after buying an additional 52,169 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of OptimizeRx in the 4th quarter valued at about $178,000. Institutional investors own 76.47% of the company's stock.

Insider Buying and Selling

In other news, Director James Paul Lang purchased 321,408 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average cost of $7.60 per share, with a total value of $2,442,700.80. Following the purchase, the director now owns 389,452 shares in the company, valued at $2,959,835.20. This represents a 472.35 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.10% of the stock is owned by company insiders.

OptimizeRx Trading Up 0.9 %

Shares of NASDAQ:OPRX traded up $0.08 during midday trading on Monday, reaching $8.74. The company's stock had a trading volume of 136,124 shares, compared to its average volume of 266,694. The firm has a 50 day moving average price of $7.38 and a two-hundred day moving average price of $6.10. OptimizeRx Co. has a fifty-two week low of $3.78 and a fifty-two week high of $14.13. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The firm has a market capitalization of $161.60 million, a price-to-earnings ratio of -6.57 and a beta of 1.18.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. JMP Securities reiterated a "market outperform" rating and issued a $8.00 price target on shares of OptimizeRx in a research report on Thursday, February 6th. B. Riley upgraded OptimizeRx to a "strong-buy" rating in a research report on Wednesday, March 12th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $6.00 price target (down previously from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.06.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.